Alpha Tau's Alpha DaRT Combination Therapy Achieves 100% Response Rate in Head and Neck Cancer Study — Alpha Tau Medical Ltd.

Event summary

Alpha Tau's Alpha DaRT® in combination with pembrolizumab achieved a 100% objective response rate and 18.2-month median overall survival in elderly patients with locally advanced or metastatic head and neck cancer.
The study, presented at the AHNS 12th International Conference on Head and Neck Cancer, surpassed pre-specified success criteria with all nine evaluable patients responding to treatment.
No serious adverse events related to Alpha DaRT were observed, with only two Grade 1 (mild) adverse events reported.
The trial recruitment is now complete, meeting the Simon two-stage adaptive design's efficacy threshold.

The big picture

Alpha Tau's results position its Alpha DaRT technology as a potential game-changer in the treatment of head and neck cancer, particularly for elderly patients who may not tolerate chemotherapy. The combination with pembrolizumab, a standard-of-care checkpoint inhibitor, suggests a new paradigm for enhancing immune responses in metastatic settings. This success could accelerate Alpha Tau's discussions with regulators and expand its pipeline into other solid tumors.

What we're watching

Regulatory Strategy: Whether Alpha Tau can secure FDA approval for a larger U.S. study based on these interim results.
Clinical Validation: The pace at which additional data from ongoing combination trials will reinforce or challenge these findings.
Market Positioning: How Alpha Tau's combination therapy approach differentiates it in the competitive landscape of head and neck cancer treatments.